Another molecule that could be targeted together with BTK is the MP3K14 enzyme, a member of an alternative NFκB pathway constitutively activated in ibrutinib-resistant MCL patients due to mutations in BIRC3, TRAF2, or TRAF3 (Figure 1) (84, 85). The gene discussed is BTK; the disease is mantle cell lymphoma.